Maja Miletić

Dr. Maja Miletić

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023
Verified
Book Chapter
Open access
PDF file
ZBZvonimir Bosnic
Zvonimir Bosnic
DŠDunja Šojat
Dunja Šojat
Tomislav KurevijaTomislav Kurevija
Tomislav Kurevija
MPMarko Pirić
Marko Pirić
RBRenata Božinović
Renata Božinović
LJILJANA MAJNARICLJILJANA MAJNARIC
LJILJANA MAJNARIC
Type 2 diabetes is a complicated condition that develops as a result of the interplay of several genetic variations with a persons lifestyle and environmental circumstances. Due to its strong ties to aging, it adds to the complexity of these patients and raises the risk that geriatric diseases like sarcopenia, malnutrition, and frailty might appear in them. In fact, chronic inflammation is thought to be the primary mechanism causing metabolic and vascular alterations as people age. There is still little knowledge about the phases of chronic inflammation that influence the development of damage to target organs, and there is also limited knowledge about the relationship between chronic inflammation and metabolic diseases. The interindividual variability in type 2 diabetes patients is further exacerbated by aging-related alterations in inflammatory and metabolic markers. Clustering, or the grouping of individuals, can help identify novel type 2 diabetes phenotypes and further clarify the pathophysiological causes of the condition. The aim of this work is to identify a potential model of treatment personalization that could be especially helpful for family medicine physicians who regularly treat complex heterogeneous patients in light of the rising demand for personalized care for patients with type 2 diabetes.

12 October 2026 in Diseases
Verified
Journal Article
Open access
PDF file
ZBZvonimir Bosnic
Zvonimir Bosnic
HPHrvoje Pitlovic
Hrvoje Pitlovic
IŠIvana Šofić
Ivana Šofić
MMMaja Miletić
Maja Miletić
DMDanijel Marinčić
Danijel Marinčić
TBTatjana Bačun
Tatjana Bačun
Background: Falls in older women are multifactorial events driven by the complex interaction of age-related loss of physiological reserve, frailty, sarcopenia, chronic low-grade inflammation, multimorbidity, and medication exposure. Older women represent a substantial proportion of fall-related injuries and fractures, yet available evidence is highly heterogeneous. Since many studies focus on mixed-sex cohorts, we must differentiate women-specific findings from general geriatric data. Methods: A structured narrative review was conducted to integrate biological, clinical, and pharmacological evidence on falls in older women, focusing particularly on primary care. The initial literature search covered PubMed, Scopus, Web of Science, and Embase from January 2000 to March 2025. To ensure the integration of recent high-level evidence, a supplementary search and backward citation tracking were subsequently executed through 31 August 2026, aligning with peer-review recommendations. Women-specific evidence was prioritized over mixed-sex cohorts. Given that the review aims for an interpretive synthesis rather than quantitative effect estimation, a meta-analysis and formal risk-of-bias assessments were omitted. Discussion: Frailty and sarcopenia are consistently associated with falls and functional decline in older adults. In contrast, inflammaging and metabolic dysregulation are more strongly supported as contributors to frailty, sarcopenia, and functional vulnerability than as independently established causal determinants of falls. Medication-related fall susceptibility may arise through several mechanisms, including sedation, impaired attention and psychomotor function, orthostatic hypotension, bradycardia, electrolyte and glucose disturbances, gait impairment, and adverse skeletal effects. Psychotropic agents, anticholinergic drugs, opioids, selected cardiovascular drugs, and other fall-risk-increasing drugs warrant particular attention in patients with reduced physiological reserve. Medication review and appropriate deprescribing should be considered components of multidomain fall-prevention strategies rather than stand-alone interventions. Conclusions: The principal contribution of this review is not the identification of new individual fall-risk factors, but the integration of established biological vulnerability, functional impairment, and pharmacological burden within a sex-sensitive primary-care framework. This approach may help clinicians consider frailty, medication exposure, and women-specific modifiers simultaneously during fall-risk assessment. The proposed framework is hypothesis-generating and should not be interpreted as a prospectively validated mechanistic or prediction model.